A recent study showed that the treatment of endothelial nitric oxide synthase-knockout db/db mice with BMS002, an LPAR1/3 antagonist, attenuated the development of DN by providing protection against podocyte loss [40]. The gene discussed is NOS3; the disease is liver dysplastic nodule.